New York, Jan 5, 2026, 13:31 EST — Regular session
- Health Canada cleared Arrowhead’s Redemplo (plozasiran) for a rare triglyceride disorder, the company said
- Shares fell about 7% in regular trade after an early pop, tracking broader biotech weakness
- Focus turns to Arrowhead’s Jan. 6 obesity data webinar and its Jan. 12 presentation at the J.P. Morgan healthcare conference
Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener
The clearance gives Arrowhead another regulated market for its first commercial product, as investors shift attention from the science to execution. It also keeps the spotlight on how quickly the company can convert approvals into reimbursed prescriptions.
The selloff underscored how hard it can be for single-stock catalysts to cut through sector tape. Biotech was broadly weaker, with the SPDR S&P Biotech ETF down about 2.1% and the iShares Nasdaq Biotechnology ETF off about 1.8%, while the S&P 500 ETF was up roughly 0.7%.
Health Canada granted a Notice of Compliance — its marketing authorization — for Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides, a type of fat in the blood, in adults with familial chylomicronemia syndrome (FCS) whose standard therapies have been inadequate, Arrowhead said. The company said the drug is a small interfering RNA (siRNA) therapy — a gene-silencing approach that blocks production of a target protein — and can be self-administered by subcutaneous injection once every three months; it added that FCS is underdiagnosed and estimated at 1 to 13 people per million globally. “We are thrilled to start the new year with Health Canada’s approval of REDEMPLO,” Chief Executive Christopher Anzalone said. Business Wire
In the United States, where the FDA approved Redemplo on Nov. 18, the company has positioned the quarterly dosing schedule against Ionis Pharmaceuticals’ monthly injectable Tryngolza, Reuters reported. Anzalone told analysts the annual wholesale cost of Redemplo is $60,000, and analysts on average expect the drug to generate about $1.4 billion in sales by 2031, according to LSEG data cited by Reuters. Reuters
For traders, the immediate question is whether Monday’s reversal is a one-day “sell the news” move or the start of a deeper pullback after a sharp run into the approval cycle. Bulls will look for the stock to reclaim the low-$70s area, while dip buyers are watching whether it can hold above the low-$60s after Monday’s intraday low.
But approval does not automatically translate into a smooth launch. FCS is rare and often missed in diagnosis, and reimbursement decisions, patient identification and competition in lipid disorders can slow early demand even with a less frequent dosing schedule.
